Designation applies to the treatment of adult patients with recurrent or metastatic head and neck squamous cell carcinoma ...

Pyxis Oncology (PYXS) announced that the U.S. Food and Drug Administration has granted Fast Track Designation to PYX-201 for the treatment of ...

Pyxis Oncology (PYXS) stock rises as the FDA issues fast track designation for its lead asset PYX-201 in head and neck cancer ...

头颈部鳞状细胞癌（HNSCC）是全球第六大常见癌症，初始治疗后复发和转移率高，是一个重要的健康问题。这些患者的中位总生存期不到一年，凸显了新治疗方案的迫切需求。虽然Pyxis Oncology的股票面临挑战，目前交易价格接近52周低点1.19美元，但 InvestingPro 分析表明该公司目前被低估。在 最被低估股票 页面了解更多被低估机会。

Shares of Pyxis Oncology, Inc. (NASDAQ:PYXS – Get Free Report) have received an average recommendation of “Moderate Buy” from ...

A jury has convened in London for an ancient ceremony to certify that British coins meet the strictest of standards.

(Nasdaq: PYXS), a clinical-stage company developing next-generation therapeutics for difficult-to-treat cancers, today announced significant progress in its clinical program for PYX-201 ...

Held at Goldsmiths’ Hall in London yesterday (11 February), the annual trial, which dates back to 1248, saw The Royal Mint ...

As of 7:45:11 AM GMT. Market Open.

A warden inspects commemorative500 Pound gold coins during the "Trial of the Pyx,'' a ceremony that dates to the 12th Century in which coins are weighed in order to make ...

Initiation of Phase 1/2 combination trial with PYX-201, an extracellular ADC targeting Extradomain-B Fibronectin (EDB+FN) and Merck’s KEYTRUDA® (pembrolizumab) in multiple solid tumors - Phase 1 ...